Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 34 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMA TILLEUL from Montigny-le-Tilleul, company number BE1016644429, closed financial year 2025 with a result of € 52,374 after tax. For that financial year PHARMA TILLEUL recorded a gross margin of € 329,577 and equity of € 52,374. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.
€ 52,374
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 52,374
Profit after tax over the fiscal year.
€ 39,136
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 52,374.
People and assets in 2025
2.4
Average over the fiscal year, from the social balance sheet.
€ 206,956
€ 86,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 63,177
Supplier invoices still open on the last day of the fiscal year.
€ 33,219
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to PHARMA TILLEUL?
What happened at PHARMA TILLEUL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 52,374. filed late Source: NBB ↗
- New establishment in Montigny-le-Tilleul. KBO
- Start of the company according to the CBE. KBO
In short
Paid € 18,889 in corporate taxes since 2025.
On average € 137,300 of value added per employee in 2025.
A new publication or filing at PHARMA TILLEUL? We notify you, reason included.
Follow PHARMA TILLEULDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Establishments
Establishment units
Physical locations of this company
Rue du Faubourg 129
6110 Montigny-le-Tilleul
Rue de Landelies 14
6110 Montigny-le-Tilleul
Active since 26 November 2024
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1016.644.429
- VAT number
- BE 1016.644.429
- Registered office
- Rue du Faubourg 129, 6110 Montigny-le-Tilleul
- Names & denominations
- PHARMA TILLEUL
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 November 2024
- Peppol
- Active · Active since 25 Nov 2025
- Activities · NACE
Detailhandel in farmaceutische producten